A related compound, camostat, is also known to enzymatically inhibit TMPRSS2, and was recently shown to block acute SARS-CoV-2 infection9, prompting the initiation of a clinical trial for this agent in COVID-19 patients (ClinicalTrials.gov Identifier: NCT04321096). This evidence concerns the gene TMPRSS2 and COVID-19.